Jardiance

empagliflozin
SGLT2 Inhibitor Boehringer Ingelheim FDA Monitored

Safety Profile Overview

SGLT2 inhibitor for type 2 diabetes with proven cardiovascular and heart failure benefits. Monitored for ketoacidosis and urinary tract infections.

Generic Name
empagliflozin
Brand Names
Jardiance
Therapeutic Class
SGLT2 Inhibitor
Manufacturer
Boehringer Ingelheim

What Pharma Signal Tracks for Jardiance

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Jardiance Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Jardiance.

curl "https://api.pharma-signal.com/drug/safety/jardiance" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Jardiance against other SGLT2 Inhibitor drugs, or explore the full manufacturer portfolio for Boehringer Ingelheim.